Eli Lilly is building a $5 billion manufacturing facility in Richmond, Va. It is the company’s first fully integrated facility for active pharmaceutical ingredients.  The site is also intended to support the drugmaker’s bioconjugate platform and monoclonal antibody portfolio, including antibody drug conjugates for cancer, autoimmune diseases and other conditions, according to an Sept. 16 news release from Eli Lilly. 

The project is a part of Eli Lilly’s effort to expand domestic pharmaceutical manufacturing, with this being the first of four sites the company plans to announce this year. The new integrated facility is expected to be up and running within five years. The post Eli Lilly plans $5B API plant in Virginia appeared first on Becker's Hospital Review | Healthcare News & Analysis.

See Full Page